The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application

By J. Lund, D. Richardson, T. Stürmer. Current Epidemiology Reports, 2015

614 citations recorded by the source corpus.

Better understanding of biases related to selective prescribing of, and adherence to, preventive treatments has led to improvements in the design and analysis of pharmacoepidemiologic studies. One influential development has been the “active comparator, new user” study design, which seeks to emulate the design of a head-to-head randomized controlled trial. In this review, we first discuss biases that may affect pharmacoepidemiologic studies and describe their direction and magnitude in a variety of settings. We then present the historical foundations of the active comparator, new user study design and explain how this design conceptually mitigates biases leading to a paradigm shift in pharmacoepidemiology. We offer practical guidance on the implementation of the study design using administrative databases. Finally, we provide an empirical example in which the active comparator, new user study design addresses biases that have previously impeded pharmacoepidemiologic studies.

Subfields: Economics and Econometrics, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/091863835794fe295a0cd0fcc5ec398435620286

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

In Statistics and Probability

Citations in the corpus

Precision Medicine. (2019, background): “These designs can also include careful selection of subsets of convenience samples to improve quality of causal inference, as done, for example in Lund et al (2015).”